Hochschulschrift
Investigation of PET-based treatment planning in peptide-receptor radionuclide therapy (PRRT) using a physiologically based pharmacokinetic (PBPK) model
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Maße
-
30 cm
- Umfang
-
vi, 56 Blätter
- Sprache
-
Englisch
- Anmerkungen
-
Diagramme
Ruprecht-Karls-Universität zu Heidelberg, Dissertation, 2016
- Klassifikation
-
Medizin, Gesundheit
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 14:09 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
Entstanden
- 2016
Ähnliche Objekte (12)
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Optimisation of molecular radiotherapy for leukaemia patients using physiologically based pharmacokinetic models
Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution
Physiologically based pharmacokinetic (PBPK) modeling for dynamical liver function tests and CYP phenotyping
Physiologically based pharmacokinetic modelling in health and disease for the support of pharmacotherapy
Physiologically based pharmacokinetic modeling for the optimization of 212Pb-based targeted alpha-particle therapy in small animals
Physiologically-based pharmacokinetic and mechanism-based pharmacodynamic modelling of monoclonal antibodies with a focus on tumour targeting
Important pharmacokinetic parameters for individualization of 177Lu‐PSMA therapy: a global sensitivity analysis for a physiologically‐based pharmacokinetic model
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Development and evaluation of a physiologically based pharmacokinetic model for populations of pregnant women
Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development and Research: Methodology, Applications, and Limitations
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Optimisation of molecular radiotherapy for leukaemia patients using physiologically based pharmacokinetic models
Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution
Physiologically based pharmacokinetic (PBPK) modeling for dynamical liver function tests and CYP phenotyping
Physiologically based pharmacokinetic modelling in health and disease for the support of pharmacotherapy
Physiologically based pharmacokinetic modeling for the optimization of 212Pb-based targeted alpha-particle therapy in small animals
Physiologically-based pharmacokinetic and mechanism-based pharmacodynamic modelling of monoclonal antibodies with a focus on tumour targeting
Important pharmacokinetic parameters for individualization of 177Lu‐PSMA therapy: a global sensitivity analysis for a physiologically‐based pharmacokinetic model
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Development and evaluation of a physiologically based pharmacokinetic model for populations of pregnant women
Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development and Research: Methodology, Applications, and Limitations
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Optimisation of molecular radiotherapy for leukaemia patients using physiologically based pharmacokinetic models
Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution
Physiologically based pharmacokinetic (PBPK) modeling for dynamical liver function tests and CYP phenotyping
Physiologically based pharmacokinetic modelling in health and disease for the support of pharmacotherapy
Physiologically based pharmacokinetic modeling for the optimization of 212Pb-based targeted alpha-particle therapy in small animals
Physiologically-based pharmacokinetic and mechanism-based pharmacodynamic modelling of monoclonal antibodies with a focus on tumour targeting
Important pharmacokinetic parameters for individualization of 177Lu‐PSMA therapy: a global sensitivity analysis for a physiologically‐based pharmacokinetic model
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Development and evaluation of a physiologically based pharmacokinetic model for populations of pregnant women